← All Johnson & Johnson filings

Johnson & Johnson Schedule 13G passive stakes

Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.

NYSE
JNJ
Johnson & Johnson
SCHEDULE: Vanguard Discloses 7.49% Stake in Johnson & Johnson
Vanguard Capital Management has filed a Schedule 13G reporting a 7.49% beneficial ownership stake in Johnson & Johnson common stock.
NYSE
JNJ
Johnson & Johnson
SCHEDULE: Johnson & Johnson Amends SEC Filing for Rallybio Stake
Johnson & Johnson and its subsidiary JJDC have amended their Schedule 13G filing, reporting a combined beneficial ownership of 2.9% in Rallybio Corporation as of March 31, 2026.
NYSE
JNJ
Johnson & Johnson
SCHEDULE: Vanguard Group Reports Zero J&J Stake After Internal Realignment
The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Johnson & Johnson following an internal realignment that disaggregated reporting responsibilities.
NYSE
JNJ
Johnson & Johnson
SCHEDULE: Vanguard Amends J&J Stake, Discloses Internal Realignment
The Vanguard Group filed an amended Schedule 13G for Johnson & Johnson, reporting a 10.1% beneficial ownership and detailing an internal realignment affecting its reporting structure.
NYSE
JNJ
Johnson & Johnson
SCHEDULE: Johnson & Johnson Maintains 15.4% Stake in CVRx
Johnson & Johnson and its subsidiary JJDC, Inc. have filed an amendment to their Schedule 13G, confirming a 15.4% beneficial ownership in CVRx, Inc.
NYSE
JNJ
Johnson & Johnson
SCHEDULE: J&J Reduces Stake in Rapport Therapeutics to 4.9%
Johnson & Johnson and its subsidiary JJDC have reduced their beneficial ownership in Rapport Therapeutics, Inc. to 4.9% of common stock.